医疗行业正经历深刻的模式转变，消费者需求、远程医疗和商业利益日益主导药物与治疗产品的获取方式，打破了传统由医生主导的临床诊疗格局。1在澳大利亚，制药公司礼来推出了LillyDirect平台，患者可在线上传处方、获得Mounjaro（替扎帕肽），并直接送达家中。1这一转变涉及多种药物，包括医用大麻、GLP-1减肥药、氯胺酮、迷幻药、睾酮和肽类等。1虽然这种创新提高了某些药物的可及性，但也伴随着新的安全隐患。
医疗专业人士担忧分离的服务模式可能削弱患者护理的连续性。1全科医生和药剂师指出，处方、配药和临床护理的分离会导致监督缺失和用药安全风险。1患者可能在充分的安全有效证据出现之前使用药物，对长期伤害、药物相互作用或治疗的终止时间一无所知。1医疗大麻的使用数据显示快速增长，应用于精神健康、慢性疼痛和睡眠障碍等多个领域，但现有系统无法追踪个别患者的治疗情况和后续结果。1GLP-1药物虽在糖尿病和肥胖症治疗中有强有力证据支持，但使用范围正扩展至物质使用障碍和阿尔茨海默病等未获批的适应症。1此外，社交媒体营销还推动了低睾酮治疗的使用，将其与自我优化和身体形象相关联。1业界呼吁加强证据基础、完善安全监测体系和系统集成，以在推动创新的同时保护患者安全。1
The healthcare sector is undergoing a significant transformation in how medications and treatments reach patients, with consumer preferences, telemedicine, and commercial interests increasingly displacing the traditional doctor-led clinical model.1 Pharmaceutical companies such as Eli Lilly have pioneered direct-to-consumer platforms; the company's LillyDirect service in Australia allows patients to upload prescriptions online and receive Mounjaro (tirzepatide) delivered directly to their homes.1
While this shift has expanded access to certain medications, it has introduced a range of new safety concerns.1 Physicians and pharmacists worry that the separation of prescribing, dispensing, and clinical care has fractured continuity of treatment.1 Patients may use medications before sufficient safety and efficacy evidence exists, without awareness of long-term harms, drug interactions, or when therapy should cease.1 The medicines at the center of this transformation include GLP-1 weight-loss drugs, medical cannabis, ketamine, psychedelics, testosterone, and peptides.1
Medical cannabis data illustrates the scale of this shift, with rapid growth reported for uses including mental health, chronic pain, and sleep disorders, yet individual patient outcomes and treatment trajectories remain untracked.1 Although GLP-1 medications have strong evidence supporting their use for diabetes and obesity, their application is expanding to unapproved conditions such as substance use disorder and Alzheimer's disease.1 Social media marketing has similarly driven testosterone treatment uptake, linking low testosterone therapy to self-optimization and body image concerns.1 Addressing these risks requires better evidence, enhanced safety monitoring, and integrated health systems to ensure innovation does not compromise patient protection.1
评论
还没有评论，欢迎留下第一条。